Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-32390822

ABSTRACT

Alzheimer's disease is regarded as a synaptopathy with a long presymptomatic phase. Soluble, oligomeric amyloid-ß (Aß) is thought to play a causative role in this disease, which eventually leads to cognitive decline. However, most animal studies have employed mice expressing high levels of the Aß precursor protein (APP) transgene to drive pathology. Here, to understand how the principal neurons in different brain regions cope with moderate, chronically present levels of Aß, we employed transgenic mice expressing equal levels of mouse and human APP carrying a combination of three familial AD (FAD)-linked mutations (Swedish, Dutch, and London), that develop plaques only in old age. We analyzed dendritic spine parameters in hippocampal and cortical brain regions after targeted expression of EGFP to allow high-resolution imaging, followed by algorithm-based evaluation of mice of both sexes from adolescence to old age. We report that Aß species gradually accumulated throughout the life of APPSDL mice, but not the oligomeric forms, and that the amount of membrane-associated oligomers decreased at the onset of plaque formation. We observed an age-dependent loss of thin spines under most conditions as an indicator of a loss of synaptic plasticity in older mice. We further found that hippocampal pyramidal neurons respond to increased Aß levels by lowering spine density and shifting spine morphology, which reached significance in the CA1 subfield. In contrast, the spine density in cortical pyramidal neurons of APPSDL mice was unchanged. We also observed an increase in the protein levels of PSD-95 and Arc in the hippocampus and cortex, respectively. Our data demonstrated that increased concentrations of Aß have diverse effects on dendritic spines in the brain and suggest that hippocampal and cortical neurons have different adaptive and compensatory capacity during their lifetime. Our data also indicated that spine morphology differs between sexes in a region-specific manner.

2.
Neuropharmacology ; 113(Pt A): 434-444, 2017 02.
Article in English | MEDLINE | ID: mdl-27773645

ABSTRACT

DMSO has a widespread use as a vehicle for water-insoluble therapeutic drug candidates but may also exert disease-relevant pharmacological effects by itself. However, its influence on the CNS has hardly been addressed. Here we examined the brain structure and function following chronic exposure to low DMSO dose at a paradigm with flawed synaptic connectivity in a preclinical transgenic mouse model for Alzheimer's disease (APPSDL mice). DMSO treatment increased spine density in a region-specific manner in the hippocampus of APPSDL mice ex vivo and in vivo. Moreover, DMSO exhibited clear influence on the behavior of this mouse line by enhancing hippocampal-dependent spatial memory accuracy, modulating hippocampal-independent olfactory habituation and displaying anxiolytic effect. Despite that most of the action of DMSO was observed in animals with elevated Aß levels, the drug did not exert its function via decreasing the oligomeric Aß species. However, challenging organotypic hippocampal slice cultures with NMDA receptor antagonist MK-801 recapitulated the effect of DMSO on spine density, indicating a tuning influence of DMSO on receptor signalization. Our findings demonstrate that DMSO should be considered as a true bioactive compound, which has the potential to be a beneficial adjuvant to counteract Aß-mediated synaptotoxicity and behavioral impairment.


Subject(s)
Alzheimer Disease/drug therapy , Dendritic Spines/drug effects , Dimethyl Sulfoxide/therapeutic use , Disease Models, Animal , Hippocampus/drug effects , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Animals , Dendritic Spines/pathology , Dimethyl Sulfoxide/pharmacology , Drug Evaluation, Preclinical/methods , Free Radical Scavengers/pharmacology , Free Radical Scavengers/therapeutic use , Hippocampus/pathology , Male , Mice , Mice, Transgenic , Organ Culture Techniques , Spatial Memory/drug effects , Spatial Memory/physiology
3.
Neuropharmacology ; 105: 84-95, 2016 06.
Article in English | MEDLINE | ID: mdl-26772969

ABSTRACT

Dendritic spines represent the major postsynaptic input of excitatory synapses. Loss of spines and changes in their morphology correlate with cognitive impairment in Alzheimer's disease (AD) and are thought to occur early during pathology. Therapeutic intervention at a preclinical stage of AD to modify spine changes might thus be warranted. To follow the development and to potentially interfere with spine changes over time, we established a long term ex vivo model from organotypic cultures of the hippocampus from APP transgenic and control mice. The cultures exhibit spine loss in principal hippocampal neurons, which closely resembles the changes occurring in vivo, and spine morphology progressively changes from mushroom-shaped to stubby. We demonstrate that spine changes are completely reversed within few days after blocking amyloid-ß (Aß) production with the gamma-secretase inhibitor DAPT. We show that the microtubule disrupting drug nocodazole leads to spine loss similar to Aß expressing cultures and suppresses DAPT-mediated spine recovery in slices from APP transgenic mice. Finally, we report that epothilone D (EpoD) at a subnanomolar concentration, which slightly stabilizes microtubules in model neurons, completely reverses Aß-induced spine loss and increases thin spine density. Taken together the data indicate that Aß causes spine changes by microtubule destabilization and that spine recovery requires microtubule polymerization. Moreover, our results suggest that a low, subtoxic concentration of EpoD is sufficient to reduce spine loss during the preclinical stage of AD.


Subject(s)
Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/metabolism , Dendritic Spines/drug effects , Dendritic Spines/pathology , Epothilones/pharmacology , Hippocampus/drug effects , Hippocampus/pathology , Tubulin Modulators/pharmacology , Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Cells, Cultured , Diamines/pharmacology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nocodazole/pharmacology , PC12 Cells , Rats , Thiazoles/pharmacology
4.
Mol Neurodegener ; 10: 60, 2015 Nov 05.
Article in English | MEDLINE | ID: mdl-26541821

ABSTRACT

BACKGROUND: Dendritic simplification, a key feature of the neurodegenerative triad of Alzheimer's disease (AD) in addition to spine changes and neuron loss, occurs in a region-specific manner. However, it is unknown how changes in dendritic complexity are mediated and how they relate to spine changes and neuron loss. RESULTS: To investigate the mechanisms of dendritic simplification in an authentic CNS environment we employed an ex vivo model, based on targeted expression of enhanced green fluorescent protein (EGFP)-tagged constructs in organotypic hippocampal slices of mice. Algorithm-based 3D reconstruction of whole neuron morphology in different hippocampal regions was performed on slices from APPSDL-transgenic and control animals. We demonstrate that induction of dendritic simplification requires the combined action of amyloid beta (Aß) and human tau. Simplification is restricted to principal neurons of the CA1 region, recapitulating the region specificity in AD patients, and occurs at sites of Schaffer collateral input. We report that γ-secretase inhibition and treatment with the NMDA-receptor antagonist, CPP, counteract dendritic simplification. The microtubule-stabilizing drug epothilone D (EpoD) induces simplification in control cultures per se. Similar morphological changes were induced by a phosphoblocking tau construct, which also increases microtubule stability. In fact, low nanomolar concentrations of naturally secreted Aß decreased phosphorylation at S262 in a cellular model, a site which is known to directly modulate tau-microtubule interactions. CONCLUSIONS: The data provide evidence that dendritic simplification is mechanistically distinct from other neurodegenerative events and involves microtubule stabilization by dendritic tau, which becomes dephosphorylated at certain sites. They imply that treatments leading to an overall decrease of tau phosphorylation might have a negative impact on neuronal connectivity.


Subject(s)
Amyloid beta-Peptides/metabolism , Dendrites/pathology , Dendritic Spines/pathology , Hippocampus/metabolism , Microtubules/metabolism , Neurons/metabolism , tau Proteins/metabolism , Alzheimer Disease/pathology , Animals , Dendrites/metabolism , Dendritic Spines/metabolism , Female , Hippocampus/pathology , Male , Mice , Microtubules/pathology , Nerve Degeneration/pathology , Neurons/pathology , Synapses/pathology
5.
Methods Mol Biol ; 846: 277-93, 2012.
Article in English | MEDLINE | ID: mdl-22367819

ABSTRACT

Dendritic spines act as sites of excitatory neuronal input in many types of neurons. Spine shape correlates with the strength and maturity of synaptic contacts. Thus, evaluation of spine morphology is relevant for studies on neuronal development, for determination of morphological correlates of learning and memory, and for analysis of mechanisms of neurodegeneration. Here, we describe a method to determine spine morphology in an ex vivo model of organotypic hippocampal slice cultures prepared from transgenic or non-transgenic mice. Spines are imaged using confocal high-resolution imaging and evaluated by algorithm-based analysis. The approach permits semiautomated determination of spine density and classification of different spine types in dendritic segments from hippocampal subregions to evaluate intrahippocampal connectivity.


Subject(s)
Animals, Newborn , Dendritic Spines/ultrastructure , Hippocampus/cytology , Histological Techniques/methods , Image Processing, Computer-Assisted/methods , Microscopy, Confocal/methods , Neural Pathways/cytology , Animals , Cell Culture Techniques/methods , Dendritic Spines/classification , Mice , Mice, Inbred C57BL
6.
J Cell Biol ; 192(4): 647-61, 2011 Feb 21.
Article in English | MEDLINE | ID: mdl-21339331

ABSTRACT

Changes of the microtubule-associated protein tau are central in Alzheimer's disease (AD) and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17). However, the functional consequence of the FTDP-17 tau mutation R406W, which causes a tauopathy clinically resembling AD, is not well understood. We find that the R406W mutation does not affect microtubule interaction but abolishes tau's membrane binding. Loss of binding is associated with decreased trapping at the tip of neurites and increased length fluctuations during process growth. Tandem affinity purification tag purification and mass spectrometry identify the calcium-regulated plasma membrane-binding protein annexin A2 (AnxA2) as a potential interaction partner of tau. Consistently, wild-type tau but not R406W tau interacts with AnxA2 in a heterologous yeast expression system. Sequestration of Ca(2+) or knockdown of AnxA2 abolishes the differential trapping of wild-type and R406W tau. We suggest that the pathological effect of the R406W mutation is caused by impaired membrane binding, which involves a functional interaction with AnxA2 as a membrane-cytoskeleton linker.


Subject(s)
Amino Acid Substitution , Cell Membrane/metabolism , tau Proteins/genetics , Amino Acid Sequence , Animals , Annexin A2/chemistry , Annexin A2/metabolism , Annexin A2/physiology , Binding Sites , Humans , Microtubules/metabolism , Microtubules/ultrastructure , Molecular Sequence Data , Neurites/metabolism , PC12 Cells , Phosphorylation , Rats , tau Proteins/chemistry , tau Proteins/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...